# Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma

> **NCT06595108** · NA · RECRUITING · sponsor: **Yonsei University** · enrollment: 33 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Chemotherapy
- Stereotactic Body Radiotherapy

## Interventions

- **RADIATION:** Stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT06595108
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-28
- **Primary completion:** 2027-04-25
- **Final completion:** 2028-03-27
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06595108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06595108, "Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06595108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*